President and CEO of $CHTR Makes Insider Purchase of 3,670 Shares

Christopher L. Winfrey, the Chief Executive Officer and President of $CHTR, recently acquired 3,670 shares of the company on July 31, 2025, amounting to a total of $1,002,258. This purchase, as noted in a recent SEC filing analyzed by Quiver Quantitative, equated to a 5.5% increase in the number of shares he holds, now totaling 70,243 shares of this particular class of $CHTR stock.

The activity of insiders within the $CHTR company has been witnessed on two occasions over the past six months, with one instance of a purchase and the other a sale. These transactions included Winfrey’s acquisition of 3,670 shares and Richard J. DiGeronimo, the President-Product & Technology, selling 1,551 shares.

A detailed summary of hedge fund activity concerning $CHTR showcased 420 institutional investors augmenting their holdings of $CHTR stock in the most recent quarter, while 395 reduced their stake. Significant changes were seen in entities like CAPITAL RESEARCH GLOBAL INVESTORS who added 1,626,990 shares in Q1 2025 and EAGLE CAPITAL MANAGEMENT LLC, who decreased their position by 930,540 shares in the same quarter.

Moreover, Congressional members engaged in stock trading related to $CHTR twice in the last six months, with one instance of purchase and another of sale. Notable transactions included Representative Jefferson Shreve selling up to $50,000 on May 12, and Representative Robert Bresnahan purchasing up to $15,000 on April 8.

Financial analysts from various firms have issued reports regarding $CHTR in recent months, with differing perspectives. The company received Buy ratings from three firms and a Sell rating from one. Notable ratings include Barclays’ “Underweight” rating, B of A Securities’ “Buy” rating, Loop Capital’s “Buy” rating, and Citigroup’s “Buy” rating.

Multiple analysts have also provided price targets for $CHTR recently, with a median target of $407.5. Notable price targets include Kannan Venkateshwar’s target price of $275.0, John Hodulik’s target price of $355.0, and Jonathan Atkin’s target price of $370.0, alongside Jessica Ehrlich’s target price of $500.0, Alan Gould’s target price of $510.0, and Steven Cahall’s target price of $400.0.

In conclusion, it is essential to note that the article serves as informative content on various financial activities surrounding $CHTR and should not be construed as financial advice. For further insights and data, interested individuals can refer to Quiver Quantitative’s disclaimers.